<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36015078</PMID><DateRevised><Year>2022</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">931</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph15080931</ELocationID><Abstract><AbstractText>We have previously demonstrated that platelet-poor plasma (PPP) obtained from patients with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is characterized by a hypercoagulable state and contains hyperactivated platelets and considerable numbers of already-formed amyloid fibrin(ogen) or fibrinaloid microclots. Due to the substantial overlap in symptoms and etiology between Long COVID/PASC and ME/CFS, we investigated whether coagulopathies reflected in Long COVID/PASC-hypercoagulability, platelet hyperactivation, and fibrinaloid microclot formation-were present in individuals with ME/CFS and gender- and age-matched healthy controls. ME/CFS samples showed significant hypercoagulability as judged by thromboelastography of both whole blood and platelet-poor plasma. The area of plasma images containing fibrinaloid microclots was commonly more than 10-fold greater in untreated PPP from individuals with ME/CFS than in that of healthy controls. A similar difference was found when the plasma samples were treated with thrombin. Using fluorescently labelled PAC-1, which recognizes glycoprotein IIb/IIIa, and CD62P, which binds P-selectin, we observed hyperactivation of platelets in ME/CFS hematocrit samples. Using a quantitative scoring system, the ME/CFS platelets were found to have a mean spreading score of 2.72 &#xb1; 1.24 vs. 1.00 (activation with pseudopodia formation) for healthy controls. We conclude that ME/CFS is accompanied by substantial and measurable changes in coagulability, platelet hyperactivation, and fibrinaloid microclot formation. However, the fibrinaloid microclot load was not as great as was previously noted in Long COVID/PASC. Fibrinaloid microclots, in particular, may contribute to many ME/CFS symptoms, such as fatigue, seen in patients with ME/CFS, via the (temporary) blockage of microcapillaries and hence ischemia. Furthermore, fibrinaloid microclots might damage the endothelium. The discovery of these biomarkers represents an important development in ME/CFS research. It also points to possible uses for treatment strategies using known drugs and/or nutraceuticals that target systemic vascular pathology and endothelial inflammation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nunes</LastName><ForeName>Jean M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch 7602, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kruger</LastName><ForeName>Arneaux</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch 7602, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proal</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>PolyBio Research Foundation, 7900 SE 28th ST, Suite 412, Mercer Island, WA 98040, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kell</LastName><ForeName>Douglas B</ForeName><Initials>DB</Initials><Identifier Source="ORCID">0000-0001-5838-7963</Identifier><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch 7602, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Crown St., Liverpool L69 7ZB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Novo Nordisk Foundation Centre for Biosustainability, Technical University of Denmark, Building 220, Chemitorvet 200, 2800 Kongens Lyngby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pretorius</LastName><ForeName>Etheresia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9108-2384</Identifier><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch 7602, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Crown St., Liverpool L69 7ZB, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NNF10CC1016517</GrantID><Agency>Novo Nordisk Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">fibrinaloid microclots</Keyword><Keyword MajorTopicYN="N">hypercoagulability</Keyword><Keyword MajorTopicYN="N">myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)</Keyword><Keyword MajorTopicYN="N">platelets</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36015078</ArticleId><ArticleId IdType="pmc">PMC9413879</ArticleId><ArticleId IdType="doi">10.3390/ph15080931</ArticleId><ArticleId IdType="pii">ph15080931</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bested A.C., Marshall L.M. Review of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: An evidence-based approach to diagnosis and management by clinicians. Rev. Environ. Health. 2015;30:223&#x2013;249. doi: 10.1515/reveh-2015-0026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/reveh-2015-0026</ArticleId><ArticleId IdType="pubmed">26613325</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton E.W. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: An IOM report on redefining an illness. JAMA. 2015;313:1101&#x2013;1102. doi: 10.1001/jama.2015.1346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.1346</ArticleId><ArticleId IdType="pubmed">25668027</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston S., Brenu E.W., Staines D., Marshall-Gradisnik S. The prevalence of chronic fatigue syndrome/myalgic encephalomyelitis: A meta-analysis. Clin. Epidemiol. 2013;5:105&#x2013;110. doi: 10.2147/CLEP.S39876.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S39876</ArticleId><ArticleId IdType="pmc">PMC3616604</ArticleId><ArticleId IdType="pubmed">23576883</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim E.J., Ahn Y.C., Jang E.S., Lee S.W., Lee S.H., Son C.G. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) J. Transl. Med. 2020;18:100. doi: 10.1186/s12967-020-02269-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02269-0</ArticleId><ArticleId IdType="pmc">PMC7038594</ArticleId><ArticleId IdType="pubmed">32093722</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason L.A., Mirin A.A. Updating the National Academy of Medicine ME/CFS prevalence and economic impact figures to account for population growth and inflation. Fatigue Biomed. Health Behav. 2021;9:9&#x2013;13. doi: 10.1080/21641846.2021.1878716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2021.1878716</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirin A.A., Dimmock M.E., Jason L.A. Updated ME/CFS prevalence estimates reflecting post-COVID increases and associated economic costs and funding implications. Fatigue Biomed. Health Behav. 2022;10:83&#x2013;93. doi: 10.1080/21641846.2022.2062169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2022.2062169</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia J., Chia A., Voeller M., Lee T., Chang R. Acute enterovirus infection followed by myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and viral persistence. J. Clin. Pathol. 2010;63:165&#x2013;168. doi: 10.1136/jcp.2009.070466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.2009.070466</ArticleId><ArticleId IdType="pubmed">19828908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr J. Early Growth Response Gene Upregulation in Epstein-Barr Virus (EBV)-Associated Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Biomolecules. 2020;10:1484. doi: 10.3390/biom10111484.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10111484</ArticleId><ArticleId IdType="pmc">PMC7692278</ArticleId><ArticleId IdType="pubmed">33114612</ArticleId></ArticleIdList></Reference><Reference><Citation>Shikova E., Reshkova V., Kumanova A.C., Raleva S., Alexandrova D., Capo N. Cytomegalovirus, Epstein-Barr virus, and human herpesvirus-6 infections in patients with myalgic small ie, Cyrillicncephalomyelitis/chronic fatigue syndrome. J. Med. Virol. 2020;92:3682&#x2013;3688. doi: 10.1002/jmv.25744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25744</ArticleId><ArticleId IdType="pmc">PMC7687071</ArticleId><ArticleId IdType="pubmed">32129496</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza M.E. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Human Herpesviruses Are Back! Biomolecules. 2021;11:185. doi: 10.3390/biom11020185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11020185</ArticleId><ArticleId IdType="pmc">PMC7912523</ArticleId><ArticleId IdType="pubmed">33572802</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasa S., Nora-Krukle Z., Henning N., Eliassen E., Shikova E., Harrer T. Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) J. Transl. Med. 2018;16:268. doi: 10.1186/s12967-018-1644-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1644-y</ArticleId><ArticleId IdType="pmc">PMC6167797</ArticleId><ArticleId IdType="pubmed">30285773</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A., Marshall T. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the Era of the Human Microbiome: Persistent Pathogens Drive Chronic Symptoms by Interfering With Host Metabolism, Gene Expression, and Immunity. Front. Pediatr. 2018;6:373. doi: 10.3389/fped.2018.00373.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2018.00373</ArticleId><ArticleId IdType="pmc">PMC6288442</ArticleId><ArticleId IdType="pubmed">30564562</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Twisk F.N., Kubera M., Ringel K., Leunis J.C., Geffard M. Increased IgA responses to the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated immunity in chronic fatigue syndrome. J. Affect. Disord. 2012;136:909&#x2013;917. doi: 10.1016/j.jad.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2011.09.010</ArticleId><ArticleId IdType="pubmed">21967891</ArticleId></ArticleIdList></Reference><Reference><Citation>Giloteaux L., Goodrich J.K., Walters W.A., Levine S.M., Ley R.E., Hanson M.R. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome. 2016;4:30. doi: 10.1186/s40168-016-0171-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-016-0171-4</ArticleId><ArticleId IdType="pmc">PMC4918027</ArticleId><ArticleId IdType="pubmed">27338587</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I., Davenport T., Wakefield D., Vollmer-Conna B., Cameron B., Vernon S.D. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: Prospective cohort study. BMJ. 2006;333:575. doi: 10.1136/bmj.38933.585764.AE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38933.585764.AE</ArticleId><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Raijmakers R.P.H., Roerink M.E., Jansen A.F.M., Keijmel R., Gacesa R., Li Y. Multi-omics examination of Q fever fatigue syndrome identifies similarities with chronic fatigue syndrome. J. Transl. Med. 2020;18:448. doi: 10.1186/s12967-020-02585-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02585-5</ArticleId><ArticleId IdType="pmc">PMC7690002</ArticleId><ArticleId IdType="pubmed">33243243</ArticleId></ArticleIdList></Reference><Reference><Citation>Keijmel S.P., Saxe J., van der Meer J.W., Nikolaus S., Netea M.G., Bleijenberg G. A comparison of patients with Q fever fatigue syndrome and patients with chronic fatigue syndrome with a focus on inflammatory markers and possible fatigue perpetuating cognitions and behaviour. J. Psychosom. Res. 2015;79:295&#x2013;302. doi: 10.1016/j.jpsychores.2015.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2015.07.005</ArticleId><ArticleId IdType="pubmed">26272528</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 2022;28:1461&#x2013;1467. doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong T.L., Weitzer D.J. Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systemic Review and Comparison of Clinical Presentation and Symptomatology. Medicina. 2021;57:418. doi: 10.3390/medicina57050418.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050418</ArticleId><ArticleId IdType="pmc">PMC8145228</ArticleId><ArticleId IdType="pubmed">33925784</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt J., Blease C., Geraghty K.J. Long COVID at the crossroads: Comparisons and lessons from the treatment of patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) J. Health Psychol. 2022:13591053221084494. doi: 10.1177/13591053221084494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13591053221084494</ArticleId><ArticleId IdType="pubmed">35341334</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow A.K., Malone L.A., Kokorelis C., Petracek L.S., Eastin E.F., Lobner K.L. Long-Term COVID 19 Sequelae in Adolescents: The Overlap with Orthostatic Intolerance and ME/CFS. Curr. Pediatr. Rep. 2022;10:31&#x2013;44. doi: 10.1007/s40124-022-00261-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40124-022-00261-4</ArticleId><ArticleId IdType="pmc">PMC8906524</ArticleId><ArticleId IdType="pubmed">35287333</ArticleId></ArticleIdList></Reference><Reference><Citation>Siberry V.G.R., Rowe P.C. Pediatric Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Overlaps and Opportunities. Pediatr. Infect. Dis. J. 2022;41:e139&#x2013;e141. doi: 10.1097/INF.0000000000003477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003477</ArticleId><ArticleId IdType="pmc">PMC8919937</ArticleId><ArticleId IdType="pubmed">35121715</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor C., Freitag H., Meyer-Arndt L., Wittke K., Zoller T., Steinbeis F. Chronic COVID-19 Syndrome and Chronic Fatigue Syndrome (ME/CFS) following the first pandemic wave in Germany&#x2014;A first analysis of a prospective observational study. medRxiv. 2021 doi: 10.1101/2021.02.06.21249256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.06.21249256</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front. Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Vlok M., Venter C., Bezuidenhout J.A., Laubscher G.J., Steenkamp J. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 2021;20:172. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Laubscher G.J., Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: Origins and therapeutic implications. Biochem. J. 2022;479:537&#x2013;559. doi: 10.1042/BCJ20220016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20220016</ArticleId><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy G., Norris G., Spence V., McLaren M., Belch J.J. Is chronic fatigue syndrome associated with platelet activation? Blood Coagul. Fibrinolysis. 2006;17:89&#x2013;92. doi: 10.1097/01.mbc.0000214705.80997.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mbc.0000214705.80997.73</ArticleId><ArticleId IdType="pubmed">16479189</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenu E.W., Staines D.R., Baskurt O.K., Ashton K.J., Ramos S.B., Christy R.M. Immune and hemorheological changes in chronic fatigue syndrome. J. Transl. Med. 2010;8:1. doi: 10.1186/1479-5876-8-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-8-1</ArticleId><ArticleId IdType="pmc">PMC2829521</ArticleId><ArticleId IdType="pubmed">20064266</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer J.H., Berg D. Hypercoaguable State Associated with Active Human Herpesvirus-6 (HHV-6) Viremia in Patients with Chronic Fatigue Syndrome. J. Chronic Fatigue Syndr. 2001;8:111&#x2013;116. doi: 10.1300/J092v08n03_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1300/J092v08n03_10</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D., Berg L.H., Couvaras J., Harrison H. Chronic fatigue syndrome and/or fibromyalgia as a variation of antiphospholipid antibody syndrome: An explanatory model and approach to laboratory diagnosis. Blood Coagul. Fibrinolysis. 1999;10:435&#x2013;438. doi: 10.1097/00001721-199910000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001721-199910000-00006</ArticleId><ArticleId IdType="pubmed">10695770</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla H., Hampton D., Marques de Menezes E.G., Deng X., Montoya J.G., Anderson J. Comparative Analysis of Extracellular Vesicles in Patients with Severe and Mild Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Front. Immunol. 2022;13:841910. doi: 10.3389/fimmu.2022.841910.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.841910</ArticleId><ArticleId IdType="pmc">PMC8931328</ArticleId><ArticleId IdType="pubmed">35309313</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton D.J., Kennedy G., Chan K.K., Lang C.C., Belch J.J., Khan F. Large and small artery endothelial dysfunction in chronic fatigue syndrome. Int. J. Cardiol. 2012;154:335&#x2013;336. doi: 10.1016/j.ijcard.2011.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2011.10.030</ArticleId><ArticleId IdType="pubmed">22078396</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherbakov N., Szklarski M., Hartwig J., Sotzny F., Lorenz S., Meyer A. Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome. ESC Heart Fail. 2020;7:1064&#x2013;1071. doi: 10.1002/ehf2.12633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.12633</ArticleId><ArticleId IdType="pmc">PMC7261521</ArticleId><ArticleId IdType="pubmed">32154656</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertinat R., Villalobos-Labra R., Hofmann L., Blauensteiner J., Sepulveda N., Westermeier F. Decreased NO production in endothelial cells exposed to plasma from ME/CFS patients. Vasc. Pharm. 2022;143:106953. doi: 10.1016/j.vph.2022.106953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vph.2022.106953</ArticleId><ArticleId IdType="pubmed">35074481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes Pires M.E., Clarke S.R., Marcondes S., Gibbins J.M. Lipopolysaccharide potentiates platelet responses via toll-like receptor 4-stimulated Akt-Erk-PLA2 signalling. PLoS ONE. 2017;12:e0186981. doi: 10.1371/journal.pone.0186981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0186981</ArticleId><ArticleId IdType="pmc">PMC5685579</ArticleId><ArticleId IdType="pubmed">29136006</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Li J., Ni H. Crosstalk Between Platelets and Microbial Pathogens. Front. Immunol. 2020;11:1962. doi: 10.3389/fimmu.2020.01962.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01962</ArticleId><ArticleId IdType="pmc">PMC7426443</ArticleId><ArticleId IdType="pubmed">32849656</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., Pretorius E. A Champion of Host Defense: A Generic Large-Scale Cause for Platelet Dysfunction and Depletion in Infection. Semin. Thromb. Hemost. 2020;46:302&#x2013;319. doi: 10.1055/s-0040-1708827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1708827</ArticleId><ArticleId IdType="pmc">PMC7339151</ArticleId><ArticleId IdType="pubmed">32279287</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniak S., Mackman N. Platelets and viruses. Platelets. 2021;32:325&#x2013;330. doi: 10.1080/09537104.2021.1887842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537104.2021.1887842</ArticleId><ArticleId IdType="pmc">PMC7987802</ArticleId><ArticleId IdType="pubmed">33615982</ArticleId></ArticleIdList></Reference><Reference><Citation>Branchford B.R., Carpenter S.L. The Role of Inflammation in Venous Thromboembolism. Front. Pediatr. 2018;6:142. doi: 10.3389/fped.2018.00142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2018.00142</ArticleId><ArticleId IdType="pmc">PMC5974100</ArticleId><ArticleId IdType="pubmed">29876337</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius L., Thomson G.J.A., Adams R.C.M., Nell T.A., Laubscher W.A., Pretorius E. Platelet activity and hypercoagulation in type 2 diabetes. Cardiovasc. Diabetol. 2018;17:141. doi: 10.1186/s12933-018-0783-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-018-0783-z</ArticleId><ArticleId IdType="pmc">PMC6214175</ArticleId><ArticleId IdType="pubmed">30388964</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksu K., Donmez A., Keser G. Inflammation-induced thrombosis: Mechanisms, disease associations and management. Curr. Pharm. Des. 2012;18:1478&#x2013;1493. doi: 10.2174/138161212799504731.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161212799504731</ArticleId><ArticleId IdType="pubmed">22364132</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Pretorius E. The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen) Integr. Biol. 2015;7:24&#x2013;52. doi: 10.1039/c4ib00173g.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c4ib00173g</ArticleId><ArticleId IdType="pubmed">25335120</ArticleId></ArticleIdList></Reference><Reference><Citation>Bester J., Soma P., Kell D.B., Pretorius E. Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS) Oncotarget. 2015;6:35284&#x2013;35303. doi: 10.18632/oncotarget.6074.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.6074</ArticleId><ArticleId IdType="pmc">PMC4742105</ArticleId><ArticleId IdType="pubmed">26462180</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes J.M., Fillis T., Page M.J., Venter C., Lancry O., Kell D.B. Gingipain R1 and Lipopolysaccharide From Porphyromonas gingivalis Have Major Effects on Blood Clot Morphology and Mechanics. Front. Immunol. 2020;11:1551. doi: 10.3389/fimmu.2020.01551.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01551</ArticleId><ArticleId IdType="pmc">PMC7393971</ArticleId><ArticleId IdType="pubmed">32793214</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Ismail M.Y., Diamond A., Kapoor S., Arafah Y., Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb. Res. 2020;194:101&#x2013;115. doi: 10.1016/j.thromres.2020.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.06.029</ArticleId><ArticleId IdType="pmc">PMC7305763</ArticleId><ArticleId IdType="pubmed">32788101</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Swanepoel A.C., DeVilliers S., Bester J. Blood clot parameters: Thromboelastography and scanning electron microscopy in research and clinical practice. Thromb. Res. 2017;154:59&#x2013;63. doi: 10.1016/j.thromres.2017.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2017.04.005</ArticleId><ArticleId IdType="pubmed">28414934</ArticleId></ArticleIdList></Reference><Reference><Citation>Laubscher G.J., Lourens P.J., Venter C., Kell D.B., Pretorius E. TEG((R)), Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy. J. Clin. Med. 2021;10:5381. doi: 10.3390/jcm10225381.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10225381</ArticleId><ArticleId IdType="pmc">PMC8621180</ArticleId><ArticleId IdType="pubmed">34830660</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers B.M., van de Sande M.I., De Meirleir K.L., Klimas N.G., Broderick G., Mitchell T. Myalgic encephalomyelitis: International Consensus Criteria. J. Intern. Med. 2011;270:327&#x2013;338. doi: 10.1111/j.1365-2796.2011.02428.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2011.02428.x</ArticleId><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar L.M., Venter C., Vlok M., Ngoepe M., Laubscher G.J., Lourens P.J. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19. Biosci. Rep. 2021;41:BSR20210611. doi: 10.1042/BSR20210611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20210611</ArticleId><ArticleId IdType="pmc">PMC8380922</ArticleId><ArticleId IdType="pubmed">34328172</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Pretorius E. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: Lessons from and for blood clotting. Prog. Biophys. Mol. Biol. 2017;123:16&#x2013;41. doi: 10.1016/j.pbiomolbio.2016.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbiomolbio.2016.08.006</ArticleId><ArticleId IdType="pubmed">27554450</ArticleId></ArticleIdList></Reference><Reference><Citation>Varin R., Mirshahi S., Mirshahi P., Klein C., Jamshedov J., Chidiac J. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban. Thromb. Res. 2013;131:e100&#x2013;e109. doi: 10.1016/j.thromres.2012.11.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2012.11.029</ArticleId><ArticleId IdType="pubmed">23313382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gade Malmos K., Blancas-Mejia L.M., Weber B., Buchner J., Ramirez-Alvarado M., Naiki H. ThT 101: A primer on the use of thioflavin T to investigate amyloid formation. Amyloid. 2017;24:1&#x2013;16. doi: 10.1080/13506129.2017.1304905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13506129.2017.1304905</ArticleId><ArticleId IdType="pubmed">28393556</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Page M.J., Engelbrecht L., Ellis G.C., Kell D.B. Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains. Cardiovasc. Diabetol. 2017;16:141. doi: 10.1186/s12933-017-0624-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-017-0624-5</ArticleId><ArticleId IdType="pmc">PMC5668975</ArticleId><ArticleId IdType="pubmed">29096623</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Mbotwe S., Bester J., Robinson C.J., Kell D.B. Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide. J. R. Soc. Interface. 2016;13:20160539. doi: 10.1098/rsif.2016.0539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsif.2016.0539</ArticleId><ArticleId IdType="pmc">PMC5046953</ArticleId><ArticleId IdType="pubmed">27605168</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima M.O., Rogers H.J. Hypercoagulable states: An algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Res. 2014;49:85&#x2013;94. doi: 10.5045/br.2014.49.2.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.5045/br.2014.49.2.85</ArticleId><ArticleId IdType="pmc">PMC4090343</ArticleId><ArticleId IdType="pubmed">25025009</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>